Theta Burst Stimulation for Gambling Disorder

Sponsor
Taipei City Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05872750
Collaborator
(none)
75
1
2
37.5
2

Study Details

Study Description

Brief Summary

The goal of this clinical trial is to investigate the efficacy of theta burst stimulation in individuals with gambling disorder. The main goal is to compare the severity of gambling problems following 2 weeks of intervention between active group and sham group. Participants will be randomized into active and sham group. The severity of gambling problems are assessed by self-reported questionaires.

Condition or Disease Intervention/Treatment Phase
  • Device: theta burst stimulation
  • Device: sham stimulation
N/A

Detailed Description

Gambling disorder, formerly known as pathological gambling, is a gambling behavior that causes significant function impairment in personal, social, occupational domains. Currently there is no pharmacological treatment for gambling disorder and it is urgent to develop innovative treatment modalities. Image studies have found a link between prefrontal circuit dysfunction and behavioral disinhibition, which supports the use of non-invasive brain stimulation as a potential treatment for gambling disorder. In this study, 75 patients with gambling disorder will be randomly assigned in a 2:1 ratio to the intervention group (50 patients) and the control group (25 patients) on double-blind basis. The study duration is 2 weeks, with 10 sessions of 20 minutes each. The intervention group will receive repetitive transcranial magnetic stimulation at the left dorsolateral prefrontal cortex and pre-supplementary motor area, while the control group will receive sham stimulation. The Chinese version of the Problem Gambling Severity Index (PGSI), the Gambling Symptom Assessment Scale (G-SAS), and the Visual Analogue Scale (VAS) for craving will be administered at week 0, 2, 4, 8, and the change in gambling severity between the two groups will be compared by repeated measures ANOVA.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
75 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
theta burst stimulationtheta burst stimulation
Masking:
Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Rolling Deep With Gambling Disorder: From Building up of Scales, Biomarkers to Therapeutic Innovation
Actual Study Start Date :
Apr 17, 2023
Anticipated Primary Completion Date :
Jun 1, 2026
Anticipated Study Completion Date :
Jun 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Active arm

The intervention group will receive repetitive transcranial magnetic stimulation at the left dorsolateral prefrontal cortex and pre-supplementary motor area

Device: theta burst stimulation
Magstim Rapid 2 Plus stimulator (Magstim Co., Ltd., Whitland, United Kingdom)

Sham Comparator: Sham arm

the control group will receive sham stimulation

Device: sham stimulation
sham stimulation

Outcome Measures

Primary Outcome Measures

  1. Change in gambling craving [Before intervention (week 0) and after intervention (week 2, 4)]

    Measured by visual analog scale, from 0-10

  2. Change in gambling severity [Before intervention (week 0) and after intervention (week 2, 4)]

    Measured by Gambling Symptom Assessment Scale, from 0-48

Secondary Outcome Measures

  1. Change in depression severity [Before intervention (week 0) and after intervention (week 2, 4)]

    Measured by Beck Depression Inventory, from 0-63

  2. Change in anxiety severity [Before intervention (week 0) and after intervention (week 2, 4)]

    Measured by Beck Anxiety Inventory, from 0-63

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. age between 18 and 65 years;

  2. fulfilling at least 4 of the Diagnostic and Statistical Manual version 5 (DSM-5) criteria of gambling disorder for at least 12-month assessed by the Structured Clinical Interview

Exclusion Criteria:
  1. Inability to provide informed consent or comprehend the study procedure;

  2. A major psychiatric illness that required chronic psychotropic medication or inpatient treatment, including schizophrenia spectrum disorder, bipolar spectrum disorder, and major depressive disorder with psychotic features.

  3. A current DSM-5 diagnosis of substance use disorder except nicotine use disorder or the use of one to two low-potency benzodiazepine tablets for sleep impairment;

  4. Have known preexisting noise-induced hearing loss, concurrent treatment with ototoxic medications, or with cochlear implants.

  5. Unstable medical illness, including malignancy, uncontrolled diabetes mellitus, unstable cardiac disease or recent myocardial infarction, or cerebrovascular or cardiovascular risk factors that require intensive medical management

  6. On medications known to lower seizure threshold (e.g., TCA, bupropion, clozapine)

  7. Implants controlled by physiological signals, including pacemaker, implantable cardioverter defibrillator, cochlear implant.

  8. Metallic objects in the head, including stenting, suture.

  9. Elevated risk of seizure due to traumatic brain history, seizure history, and head trauma, intracranial lesion, and alcohol or benzodiazepines withdrawal syndrome, stimulant intoxication.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Taipei City Hospital Taipei Taipei CITY Taiwan 105

Sponsors and Collaborators

  • Taipei City Hospital

Investigators

  • Principal Investigator: Hu-Ming Chang, Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Taipei City Hospital
ClinicalTrials.gov Identifier:
NCT05872750
Other Study ID Numbers:
  • TCHIRB-11104005
First Posted:
May 24, 2023
Last Update Posted:
May 24, 2023
Last Verified:
May 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Taipei City Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 24, 2023